TY - JOUR AU - Molnár, Ildikó TI - Nerve growth factor and its role in immunoinflammatory and endocrine metabolic diseases JF - HOJ Emergency and Internal Medicine VL - 1 PY - 2023 IS - 2 SP - 1 EP - 7 PG - 7 SN - 2995-6056 UR - https://m2.mtmt.hu/api/publication/34685331 ID - 34685331 N1 - https://scholar.googleusercontent.com/scholar?q=cache:GoerY2pN0BUJ:scholar.google.com/&hl=hu&as_sdt=0,5 LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Ildikó TI - Postmenopausal lumbar spine osteoporosis in Hungarian women is characterised by increased serum levels of nerve growth factor. JF - Int J Biomed Res Prac VL - 3 PY - 2023 IS - 1 SP - 1 EP - 7 PG - 7 SN - 2769-6294 UR - https://m2.mtmt.hu/api/publication/34685246 ID - 34685246 N1 - https://www.scivisionpub.com/pdfs/postmenopausal-lumbar-spine-osteoporosis-in-hungarian-women-is-characterised-by-increased-serum-levels-of-nerve-growth-factor-2987.pdf LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Ildikó TI - Relationship between autoantibodies against type 2 deiodinase and antithyroid autoantibodies in Graves’ disease using antithyroid drug therapy. JF - ARCHIVES OF MEDICAL RESEARCH J2 - ARCH MED RES VL - 10 PY - 2022 IS - 12 SP - 3432 EP - 3446 PG - 15 SN - 0188-4409 UR - https://m2.mtmt.hu/api/publication/33581550 ID - 33581550 LA - English DB - MTMT ER - TY - BOOK AU - Molnár, Ildikó TI - Graves' disease , ed: Robert Gensure PB - IntechOpen CY - London PY - 2021 SP - 113 UR - https://m2.mtmt.hu/api/publication/34685448 ID - 34685448 LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Ildikó TI - Interactions among thyroid hormone (FT4), chemokine (MCP-1) and neurotrophin (NGF-β) levels studied in Hungarian postmenopausal and obese women JF - CYTOKINE J2 - CYTOKINE VL - 127 PY - 2020 SP - 1 EP - 7 PG - 7 SN - 1043-4666 UR - https://m2.mtmt.hu/api/publication/31614394 ID - 31614394 LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Ildikó AU - Szentmiklósi, József András AU - Gesztelyi, Rudolf AU - Somogyine-Vari, Eva TI - Effect of antithyroid drugs on the occurrence of antibodies against type 2 deiodinase (DIO2), which are involved in hyperthyroid Graves' disease influencing the therapeutic efficacy JF - CLINICAL AND EXPERIMENTAL MEDICINE J2 - CLIN EXP MED VL - 19 PY - 2019 IS - 2 SP - 245 EP - 254 PG - 10 SN - 1591-8890 DO - 10.1007/s10238-018-00542-7 UR - https://m2.mtmt.hu/api/publication/31102623 ID - 31102623 AB - Graves' disease is an organ-specific autoimmune disease with hyperthyroidism, diffuse goiter and autoantibodies against TSH receptor, thyroid peroxidase (TPO) and/or thyroglobulin (Tg). Graves' hyperthyroidism is characterized by T-3 dominance due to the conversion of T-4 into T-3 through type 1 and 2 deiodinase enzymes (DIO1, DIO2). Methimazole (MMI) and propylthiouracil (PTU) therapies inhibit thyroid hormone synthesis blocking the activity of deiodinase and TPO enzymes. The study investigated the occurrence of autoantibodies against DIO2 peptides (cys- and hom-peptides) with the effect of antithyroid drugs on their frequencies in 78 patients with Graves' disease and 30 controls. In hyperthyroidism, the presence of DIO2 peptide antibodies was as follows: 20 and 11 cases out of 51 for cys- and hom-peptide antibodies, respectively, of whom 8 cases possessed antibodies against both peptides. Antithyroid drugs differently influenced their frequencies, which were greater in PTU than in MMI (3/6 vs 13/45 cases, P < 0.016 for cys- and 0/6 vs 2/45 cases for hom-peptide antibodies). Antibodies against both peptides demonstrated more reduced levels of anti-TPO (P < 0.003) and anti-Tg antibodies (P < 0.002) compared with those without peptide antibodies. PTU compared with MMI increased the levels of TSH receptor antibodies (32.5 UI/l vs 2.68IU/l, P < 0.009). MMI treatment led to more reduced FT3 levels and FT3/FT4 ratios in hyperthyroid Graves' ophthalmopathy (P < 0.028 for FT3, P < 0.007 for FT3/FT4 ratio). In conclusion, the presence of DIO2 peptide antibodies is connected to Graves' hyperthyroidism influencing the levels of antibodies against TPO, Tg and TSH receptor, as well as the therapeutic efficacy of antithyroid drugs. LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Ildikó AU - Szentmiklósi, József András AU - Gesztelyi, Rudolf AU - Somogyiné-Vári, Éva TI - Influencing effect of medications on the frequency of antibodies against protein sequences of type 2 deiodinase and their relationship with the thyroid hormone and antibody levels in hyperthyropid Graves' ophthalmopathy. JF - IMMUNOLÓGIAI SZEMLE J2 - IMMUNOLÓGIAI SZEMLE VL - 9 PY - 2017 IS - 3 SP - 17 EP - 18 PG - 2 SN - 2061-0203 UR - https://m2.mtmt.hu/api/publication/3282362 ID - 3282362 LA - English DB - MTMT ER - TY - DATA AU - Molnár, Ildikó TI - Immune and Metabolic Alterations Associated with Postmenopausal PY - 2017 UR - https://m2.mtmt.hu/api/publication/3276203 ID - 3276203 N1 - EC Gynaecology RCO.01 (2017): 01-03. LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Ildikó AU - Szentmiklósi, József András AU - Somogyiné-Vári, Éva TI - Hyperthyroidism in patients with Graves' ophthalmopathy, and thyroidal, skeletal and eye muscle specific type 2 deiodinase enzyme activities. JF - EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES J2 - EXP CLIN ENDOCR DIAB VL - 125 PY - 2017 IS - 8 SP - 514 EP - 521 PG - 8 SN - 0947-7349 DO - 10.1055/s-0043-113831 UR - https://m2.mtmt.hu/api/publication/3276201 ID - 3276201 AB - Graves' ophthalmopathy is characterized by hyperthyroidism, which is associated with higher serum T 3 levels than T 4 due to deiodinase enzymes. The effect of Graves' patient's sera (n=52) with elevated thyroid hormone and TSH receptor or thyroid peroxidase antibody (anti-TPO) levels was investigated on thyroidal, skeletal and eye muscle type 2 deiodinase enzyme (DII) activities. DII activities were measured with 125 I-T 4 substrate, while thyroid hormone and antibody levels with immunoassays. In Graves' ophthalmopathy, sera with elevated FT 4 or FT 3 levels reduced DII activites remarkably in all tissue fractions. Thyroidal DII activities were lower than those using eye muscle fraction (0.6±0.22 vs 1.14±0.43 pmol/mg/min, P<0.006). Effect of sera with increased FT 3 levels demonstrated also reduced DII activities in patients with Graves' ophthalmopathy after methimazole therapy compared to those who had no ophthalmopathy (2.88±2 vs 20.42±11.82 pmol/mg/min, P<0.006 for thyroidal fraction, 4.07±2.72 vs 29.22±15.46 pmol/mg/min, P<0.004 for skeletal muscle, 5.3±3.47 vs 37.87±18.82 pmol/mg/min, P<0.003 for eye muscle). Hyperthyroid sera with TSH receptor antibodies resulted in increased DII activities, while sera with anti-TPO antibodies were connected to lower DII activities in Graves' ophthalmopathy. In summary, the actions of hyperthyroid sera derived from patients with Graves' disease were tested on tissue-specific DII activities. Elevated FT 4 level-induced DII inactivation is present in Graves' ophthalmopathy, which seems to be also present at the beginning of methimazole therapy. Stimulating TSH receptor antibiodies increased DII activities via their nongenomic effects using sera of hyperthyroid Graves' ophthalmopathy, but anti-TPO antibodies could influence DII activities via altering FT 4 levels. LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Ildikó AU - Szentmiklósi, József András AU - Somogyiné-Vári, Éva TI - Antibodies against human eye muscle tissue fractions bind to type 2 5’deiodinase and inhibit the lymphocyte MAPK activation derived from hyperthyroid patients with Graves’ disease. JF - ENDOCRINE ABSTRACTS J2 - ENDOCR ABSTR VL - 41 PY - 2016 SN - 1470-3947 UR - https://m2.mtmt.hu/api/publication/3282366 ID - 3282366 LA - English DB - MTMT ER -